The study found, according to a press release, a 49 percent savings for self-funded employer groups, amounting to $1.3 million in savings every year.
The Regenexx process involves using cells from an individual’s own body to treat common orthopedic conditions, with physicians giving precise injections using platelet-rich plasma and bone marrow.
“Overuse and misuse of orthopedic surgery is prevalent in our healthcare system today. Our regenerative orthopedic approach to treating common orthopedic conditions is transforming the care pathway of an orthopedic patient who can now avoid a surgical encounter with less risk and less downtime,” Regenexx Corporate Program Founder Jason Hellickson said in the July 19 press release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
